Clinical Trials
95 trialsA Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Hoffmann-La Roche
SAMURAI
NRG Oncology
AXMUS-C
Imperial College London
NEOPAX
University of Colorado, Denver
CAPTUR
Canadian Cancer Trials Group
SPARCC
Dana-Farber Cancer Institute
An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Yonsei University
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
H. Lee Moffitt Cancer Center and Research Institute
Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
M.D. Anderson Cancer Center
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Columbia University
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy
Tianjin Medical University Cancer Institute and Hospital
Axitinib + Ipilimumab in Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
PADRES
University of California, San Diego
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
AXAGIST
Maria Sklodowska-Curie National Research Institute of Oncology
Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
Peking Union Medical College Hospital
ProTarget
Rigshospitalet, Denmark
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
AXIPAN
Assistance Publique - Hôpitaux de Paris
SABR Combined with Axitinib and Toripalimab in Recurrent or Metastatic RCC
Peking University First Hospital
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
Akeso
NPC - AXEL Study : Axitinib-Avelumab
Chinese University of Hong Kong
StrataPATH
Strata Oncology
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
Peking University Cancer Hospital & Institute
A-PREDICT
Institute of Cancer Research, United Kingdom
A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
Astellas Pharma Inc
Combination of Toripalimab and JS004 Therapy for ccRCC
Fudan University
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
M.D. Anderson Cancer Center
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
University of Miami
Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Pfizer
DRUP
The Netherlands Cancer Institute
Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
Case Comprehensive Cancer Center
AxIn
Consorzio Oncotech
Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
University of Texas Southwestern Medical Center
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
Peking Union Medical College Hospital
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
City of Hope Medical Center
AXIPAP
Centre Leon Berard
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
NYU Langone Health
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
PrE0801
PrECOG, LLC.
PANDORA
Tianjin Medical University Second Hospital
SAARCC
Tianjin Medical University Second Hospital
NAXIVA
Scottish Clinical Trials Research Unit